Clinical Trials: Leukemia

California

Duarte; City of Hope
A Multi-Center, Open-Label Phase I Study of Single Agent RO5045337 Administered Orally in Patients with Acute Myelogenous Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myelogenous Leukemia (CML)in Blast Phase, or Refractory Chronic Lymphocytic Leukemia/Small Cell Lymphocytic Lymphoma (CLL/SCLL)

Duarte; City of Hope
A Phase II Study of LBH589, a Novel Histone Deacetylase Inhibitor, in Relapsed and Refractory Adult Patients with Acute Lymphoblastic Leukemia (ALL)and Acute Myelogenous Leukemia, (AML)

Duarte; City of Hope
Understanding the Barriers and Facilitators to Adherence to Oral Chemotherapy in Youth with Acute Lymphoblastic Leukemia

Duarte; City of Hope
COG AALL03N1: Understanding the Ethnic and Racial Differences in Survival in Children with Acute Lymphoblastic Leukemia

Duarte; City of Hope
A Phase II Multicenter Trial of Myeloablative Double Unit Umbilical Cord Blood Transplantation (UCBT) in Adults with Hematologic Malignancy

Duarte; City of Hope
SWOG 9007: Cytogenetic Studies In Leukemia Patients

Duarte; City of Hope
PHI-57 NCI# 7689: Phase I Trial of GTI2040 in Relapsed, Refractory, or High Risk Leukemia and Myelodysplasia

Duarte; City of Hope
SWOG S0333: A Phase II Study of Double Induction Chemotherapy for Newly Diagnosed Non-L3 Adult Acute Lymphoblastic Leukemia with Investigation of Minimal Residual Disease and Risk of Relapse Following Maintenance Chemotherapy

Duarte; City of Hope
COG AALL0232: High Risk B-Precursor Acute Lymphoblastic Leukemia

Duarte; City of Hope
SWOG S0325: A Phase IIB Study of Molecular Responses to Imatinib at Standard or Increased Doses for Previously Untreated Patients with Chronic Myelogenous Leukemia in Chronic Phase

Duarte; City of Hope
BMT CTN 0303: A Single Arm, Multicenter Phase II Trial of Transplants of HLA-Matched, CD34+Enriched, T Cell Depleted Peripheral Blood Stem Cells Isolated by The CliniMACS System in The Treatment of Patients With AML in First or Second Morphologic Complete Remission

Duarte; City of Hope
Allogeneic Stem Cell Transplantation with a Novel Conditioning Therapy Helical Tomotherapy, Melphalan, and Fludarabine in Hematological Malignancies

Duarte; City of Hope
Phase II Trial Utilizing Idarubicin in Combination with High-Dose Ara-C for Induction Therapy for Adult Acute Myelogenous Leukemia

Duarte; City of Hope
SWOG S9910: Leukemia Centralized Reference Laboratories and Tissue Repositories, Ancillary

Duarte; City of Hope
T2005-003: A Study of Bortezomib with Chemotherapy for Relapsed/Refractory Acute Lymphoblastic Leukemia

Duarte; City of Hope
A Phase II Study of Rituximab-ABVD in Classical Hodgkin's Lymphoma

Duarte; City of Hope
COG #AAML0531: Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined with Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents and Young Adults

Duarte; City of Hope
COG AALL05B1: A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens

Duarte; City of Hope
Molecular Pathogenesis of Therapy-Related Leukemia

Duarte; City of Hope
BMT CTN #0501: Multi-Center, Open Label, Randomized Trial Comparing Single Versus Double Umbilical Cord Blood Transplantation in Pediatric Patients with High Risk Leukemia and Myelodysplasia

Duarte; City of Hope
Molecular Pathogenesis of Acute Leukemia and Myelodysplasia

Duarte; City of Hope
Mechanisms of Response and Resistance to STI571 in CML

Duarte; City of Hope
COG AALL03B1: Classification of Acute Lymphoblastic Leukemia

Duarte; City of Hope
Acquisition of Leukapheresed Peripheral Blood Mononuclear Cells from Healthy Donors for use as Support Cells in Ex-Vivo T Cell Expansions

Duarte; City of Hope
Immunophenotype and Function of Bone Marrow-Infiltrating Lymphocytes in Patients with Myeloid Leukemias

Indiana

Beech Grove; St. Francis Hospital and Health Centers
Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia in Remission

Beech Grove; St. Francis Hospital and Health Centers
Phase II Study of AS1411 Combined With Cytarabine to Treat Acute Myeloid Leukemia

Massachusetts

Boston; Boston University Medical Center
Dendritic/AML Fusion Cell Vaccine Therapy for AML Patients in First Remission: A Phase I Clinical Trial.

New York

Bronx; Biomedical Research Alliance of New York
Acute Lymphocytic Leukemia (ALL) - Refractory or Relapsed

Bronx; Biomedical Research Alliance of New York
Leukemia - Acute Lymphocytic (ALL)

Lake Success; Biomedical Research Alliance of New York
Acute Promyelocytic Leukemia (APL) - Adults

Manhasset; Biomedical Research Alliance of New York
An experimental study to determine the dosage and safety of a study drug in patients with leukemia.

New Hyde Park; Biomedical Research Alliance of New York
A study to evaluate the tolerability of a study drug to help people with B-cell lymphocytic leukemia (B-CLL)

New York; Mount Sinai Medical Center
Randomized Phase II Study of Thalidomide Versus Thalidomide Plus Fludarabine for Patients with Chronic Lymphocytic Leukemia Previously Treated with Fludarabine

New York; Columbia University Medical Center
Peripheral Blood Stem Cell Mobilization and Storage in Patients with Chronic Myelogenous Leukemia in Complete Cytogenetic Remission on Imatinib.

New York; Columbia-Presbyterian Medical Center
Study of donor leukocyte infusions in patients with recurrent or persistent hematological malignancies after allogeneic bone marrow transplantation.

New York; Columbia-Presbyterian Medical Center
Study of the use of peripheral blood stem cells for allogeneic transplantation (PBSCT) in patients with advanced hematological malignancies at increased risk of relapse or transplant-related mortality

New York; Columbia-Presbyterian Medical Center
Study of autografting for advanced phase chronic myeloid leukemia

New York; Columbia-Presbyterian Medical Center
Study of transplantation using umbilical cord and placental blood

New York; Mount Sinai Medical Center
A Phase I-II Pilot Study of Divalproex Sodium and All-Trans-Retinoic Acid (ATRA) in Relapsed or Refractory Acute Myeloid Leukemia (except M3, FAB Classification)

New York; Biomedical Research Alliance of New York
Mount Sinai Medical Center is recruiting subjects with chronic myeloid leukemia who are in blast crisis, accelerated phase, or chronic phase to participate in a clinical study to determine the safety of an experimental drug.

Ohio

Cincinnati; Cincinnati Children's Hospital Medical Center/Cincinnati Children's Research Foundation
A Phase II Study of Rituximab and Ifosfamide, Carboplatin and Etoposide (ICE) Chemotherapy In Children with Recurrent/Refractory B-cell (CD20+) Non-Hodgkin Lymphoma and B-cell Acute Lymphoblastic Leukemia

Cincinnati; Cincinnati Children's Hospital Medical Center/Cincinnati Children's Research Foundation
A Feasibility Pilot and Phase 2 Study of Chemoimmunotherapy with Epratuzumab for Children with Relapsed CD22-Positive Acute Lymphoblastic Leukemia

Cincinnati; Cincinnati Children's Hospital Medical Center/Cincinnati Children's Research Foundation
High Risk B- Precursor Acute Lymphoblastic Leukemia Study

Texas

Houston; S. R. Burzynski Clinic
Phase II Study Of Antineoplastons A10 And AS2-1 In Patients With Chronic Myelogenous Leukemia

Houston; S. R. Burzynski Clinic
Phase II Study Of Antineoplaston A10 And AS2-1 In Patients With Chronic Lymphocytic Leukemia

Virginia

Charlottesville; University of Virginia
Children over 10 years of age with ALL Leukemia sought for research study.


Back to Clinical Trials by Medical Areas

Research centers
specializing in
this illness area

Additional resources
in this illness area

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listing updated: October 6, 2008 at 3:50:32 PM

Copyright © 1995 - 2008, CenterWatch
All Rights Reserved

This site was developed in association with Illumina Interactive, Boston, MA